Alvotech SA
ALVO8.910USD
+0.120+1.37%
Market hours （ET）Quotes delayed by 15 min
2.69BMarket Cap
27.85P/E TTM
More Details of Alvotech SA Company
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Company Info
Ticker SymbolALVO
Company nameAlvotech SA
IPO dateNov 09, 2020
CEOMr. Robert (Vilhelm) Wessman
Number of employees1011
Security typeOrdinary Share
Fiscal year-endNov 09
Address9, Rue De Bitbourg
CityLUXEMBOURG
Stock exchangeNASDAQ Global Market Consolidated
CountryLuxembourg
Postal code1273
Phone35244224500
Websitehttps://www.alvotech.com/
Ticker SymbolALVO
IPO dateNov 09, 2020
CEOMr. Robert (Vilhelm) Wessman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
Mr. Benedikt Stefansson
Mr. Benedikt Stefansson
Director of Investor Relations and Global Communications
Director of Investor Relations and Global Communications
--
--
Ms. Tanya Zharov
Ms. Tanya Zharov
General Counsel
General Counsel
--
--
Mr. Faysal Kalmoua
Mr. Faysal Kalmoua
Chief Operating Officer, Executive Director
Chief Operating Officer, Executive Director
--
--
Mr. Tomas Ekman
Mr. Tomas Ekman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2024
FY2023
FY2022
No Data
By RegionUSD
Name
Revenue
Proportion
USA
273.04M
55.76%
Europe
157.59M
32.18%
Rest of the world
59.06M
12.06%
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, May 26
Updated: Mon, May 26
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Aztiq Pharma Partners SARL
33.33%
Celtic Holdings SCA
29.66%
The Vanguard Group, Inc.
1.38%
Bracebridge Capital, LLC
0.89%
Oaktree Capital Management, L.P.
0.65%
Other
34.09%
Shareholders
Shareholders
Proportion
Aztiq Pharma Partners SARL
33.33%
Celtic Holdings SCA
29.66%
The Vanguard Group, Inc.
1.38%
Bracebridge Capital, LLC
0.89%
Oaktree Capital Management, L.P.
0.65%
Other
34.09%
Shareholder Types
Shareholders
Proportion
Corporation
62.99%
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
1.94%
Hedge Fund
1.40%
Individual Investor
0.46%
Private Equity
0.43%
Research Firm
0.34%
Other
30.11%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
114
212.07M
69.88%
-4.61M
2025Q1
115
212.60M
70.06%
-4.31M
2024Q4
102
214.30M
71.08%
-114.96K
2024Q3
87
213.88M
70.94%
+661.45K
2024Q2
85
209.20M
73.73%
-4.01M
2024Q1
143
208.53M
73.94%
-24.07M
2023Q4
136
211.95M
80.98%
-21.83M
2023Q3
145
212.41M
81.19%
-22.41M
2023Q2
144
212.79M
81.57%
-23.47M
2023Q1
154
213.81M
82.04%
-23.18M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Aztiq Pharma Partners SARL
101.15M
33.33%
-2.59M
-2.49%
Mar 01, 2025
Celtic Holdings SCA
90.01M
29.66%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
4.19M
1.38%
+995.54K
+31.14%
Mar 31, 2025
Bracebridge Capital, LLC
2.71M
0.89%
--
--
Mar 31, 2025
Oaktree Capital Management, L.P.
1.97M
0.65%
-68.40K
-3.35%
Mar 31, 2025
T. Rowe Price International Ltd
1.40M
0.46%
+1.20M
+587.57%
Mar 31, 2025
Littlejohn & Co. LLC
1.32M
0.43%
--
--
Mar 31, 2025
PointState Capital LP
1.17M
0.39%
-67.04K
-5.40%
Mar 31, 2025
Davies (Richard John)
1.07M
0.35%
+19.71K
+1.88%
Mar 01, 2025
Stefnir hf.
998.47K
0.33%
-10.00K
-0.99%
May 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
ProShares Ultra Nasdaq Biotechnology
0.27%
Invesco Nasdaq Biotechnology ETF
0.27%
iShares Biotechnology ETF
0.1%
Strive Small-Cap ETF
0.04%
Schwab Emerging Markets Equity ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Vanguard Total World Stock Index Fund
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Vanguard FTSE All-World ex-US Index Fund
0%
ProShares Ultra Nasdaq Biotechnology
Proportion0.27%
Invesco Nasdaq Biotechnology ETF
Proportion0.27%
iShares Biotechnology ETF
Proportion0.1%
Strive Small-Cap ETF
Proportion0.04%
Schwab Emerging Markets Equity ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Vanguard Total World Stock Index Fund
Proportion0%
First Trust IPOX Europe Equity Opportunities ETF
Proportion0%
Vanguard FTSE All-World ex-US Index Fund
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
